Literature DB >> 21297026

Caveolin-1 deficiency exacerbates cardiac dysfunction and reduces survival in mice with myocardial infarction.

Jean-François Jasmin1, Giuseppe Rengo, Anastasios Lymperopoulos, Ratika Gupta, Gregory J Eaton, Kevin Quann, Donna M Gonzales, Isabelle Mercier, Walter J Koch, Michael P Lisanti.   

Abstract

Caveolin (Cav)-1 has been involved in the pathogenesis of ischemic injuries. For instance, modulations of Cav-1 expression have been reported in animal models of myocardial infarction and cerebral ischemia-reperfusion. Furthermore, ablation of the Cav-1 gene in mice has been shown to increase the extent of ischemic injury in models of cerebral and hindlimb ischemia. Cav-1 has also been suggested to play a role in myocardial ischemic preconditioning. However, the role of Cav-1 in myocardial ischemia (MI)-induced cardiac dysfunction still remains to be determined. We determined the outcome of a permanent left anterior descending coronary artery (LAD) ligation in Cav-1 knockout (KO) mice. Wild-type (WT) and Cav-1 KO mice were subjected to permanent LAD ligation for 24 h. The progression of ischemic injury was monitored by echocardiography, hemodynamic measurements, 2,3,5-triphenyltetrazolium chloride staining, β-binding analysis, cAMP level measurements, and Western blot analyses. Cav-1 KO mice subjected to LAD ligation display reduced survival compared with WT mice. Despite similar infarct sizes, Cav-1 KO mice subjected to MI showed reduced left ventricular (LV) ejection fraction and fractional shortening as well as increased LV end-diastolic pressures compared with their WT counterparts. Mechanistically, Cav-1 KO mice subjected to MI exhibit reduced β-adrenergic receptor density at the plasma membrane as well as decreased cAMP levels and PKA phosphorylation. In conclusion, ablation of the Cav-1 gene exacerbates cardiac dysfunction and reduces survival in mice subjected to MI. Mechanistically, Cav-1 KO mice subjected to LAD ligation display abnormalities in β-adrenergic signaling.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21297026      PMCID: PMC3075024          DOI: 10.1152/ajpheart.01173.2010

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  39 in total

1.  Sequence and expression of caveolin, a protein component of caveolae plasma membrane domains phosphorylated on tyrosine in Rous sarcoma virus-transformed fibroblasts.

Authors:  J R Glenney; D Soppet
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

2.  Caveolin-1 knockout alters beta-adrenoceptors function in mouse small intestine.

Authors:  Ahmed F El-Yazbi; Woo Jung Cho; Richard Schulz; Edwin E Daniel
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2006-06-15       Impact factor: 4.052

3.  Differential targeting of beta -adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. A mechanism to functionally regulate the cAMP signaling pathway.

Authors:  V O Rybin; X Xu; M P Lisanti; S F Steinberg
Journal:  J Biol Chem       Date:  2000-12-29       Impact factor: 5.157

4.  Receptor number and caveolar co-localization determine receptor coupling efficiency to adenylyl cyclase.

Authors:  R S Ostrom; C Gregorian; R M Drenan; Y Xiang; J W Regan; P A Insel
Journal:  J Biol Chem       Date:  2001-08-31       Impact factor: 5.157

5.  Caveolin-1 deficiency increases cerebral ischemic injury.

Authors:  Jean-François Jasmin; Samit Malhotra; Manjeet Singh Dhallu; Isabelle Mercier; Daniel M Rosenbaum; Michael P Lisanti
Journal:  Circ Res       Date:  2007-02-09       Impact factor: 17.367

6.  Nitric oxide inhibition of adenylyl cyclase type 6 activity is dependent upon lipid rafts and caveolin signaling complexes.

Authors:  Rennolds S Ostrom; Richard A Bundey; Paul A Insel
Journal:  J Biol Chem       Date:  2004-03-08       Impact factor: 5.157

7.  Cell-type and tissue-specific expression of caveolin-2. Caveolins 1 and 2 co-localize and form a stable hetero-oligomeric complex in vivo.

Authors:  P E Scherer; R Y Lewis; D Volonte; J A Engelman; F Galbiati; J Couet; D S Kohtz; E van Donselaar; P Peters; M P Lisanti
Journal:  J Biol Chem       Date:  1997-11-14       Impact factor: 5.157

8.  Caveolin-1 expression is critical for vascular endothelial growth factor-induced ischemic hindlimb collateralization and nitric oxide-mediated angiogenesis.

Authors:  Pierre Sonveaux; Philippe Martinive; Julie DeWever; Zuzana Batova; Géraldine Daneau; Michel Pelat; Philippe Ghisdal; Vincent Grégoire; Chantal Dessy; Jean-Luc Balligand; Olivier Feron
Journal:  Circ Res       Date:  2004-06-17       Impact factor: 17.367

9.  Freeze-fracture replica immunolabelling reveals caveolin-1 in the human cardiomyocyte plasma membrane.

Authors:  Horst Robenek; Gabriele Weissen-Plenz; Nicholas J Severs
Journal:  J Cell Mol Med       Date:  2008-09-13       Impact factor: 5.310

10.  Matrix metalloproteinase-2, caveolins, focal adhesion kinase and c-Kit in cells of the mouse myocardium.

Authors:  Woo Jung Cho; Ava K Chow; Richard Schulz; Edwin E Daniel
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

View more
  20 in total

1.  Hypoxia induces cardiac fibroblast proliferation and phenotypic switch: a role for caveolae and caveolin-1/PTEN mediated pathway.

Authors:  Yao Gao; Ming Chu; Jian Hong; Jingping Shang; Di Xu
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

2.  Systems analysis of gene ontology and biological pathways involved in post-myocardial infarction responses.

Authors:  Nguyen T Nguyen; Merry L Lindsey; Yu-Fang Jin
Journal:  BMC Genomics       Date:  2015-06-11       Impact factor: 3.969

3.  Caveolin-1 deletion exacerbates cardiac interstitial fibrosis by promoting M2 macrophage activation in mice after myocardial infarction.

Authors:  Pooja Shivshankar; Ganesh V Halade; Cheresa Calhoun; Gladys P Escobar; Ali J Mehr; Fabio Jimenez; Cindy Martinez; Harshita Bhatnagar; Corey H Mjaatvedt; Merry L Lindsey; Claude Jourdan Le Saux
Journal:  J Mol Cell Cardiol       Date:  2014-08-12       Impact factor: 5.000

4.  Reversal of maladaptive fibrosis and compromised ventricular function in the pressure overloaded heart by a caveolin-1 surrogate peptide.

Authors:  Dorea Pleasant-Jenkins; Charles Reese; Panneerselvem Chinnakkannu; Harinath Kasiganesan; Elena Tourkina; Stanley Hoffman; Dhandapani Kuppuswamy
Journal:  Lab Invest       Date:  2017-01-23       Impact factor: 5.662

5.  Caveolin as a potential drug target for cardiovascular protection.

Authors:  Stephanie L Sellers; Andy E Trane; Pascal N Bernatchez
Journal:  Front Physiol       Date:  2012-07-18       Impact factor: 4.566

6.  Role of caveolin-1 in atrial fibrillation as an anti-fibrotic signaling molecule in human atrial fibroblasts.

Authors:  Shao-lei Yi; Xiao-jun Liu; Jing-quan Zhong; Yun Zhang
Journal:  PLoS One       Date:  2014-01-14       Impact factor: 3.240

7.  Effects of rosuvastatin on ADMA, rhokinase, NADPH oxidase, caveolin-1, hsp 90 and NFkB levels in a rat model of myocardial ischaemia-reperfusion.

Authors:  Oktay Burma; Elif Onat; Ayhan Uysal; Necip Ilhan; Deniz Erol; Mete Ozcan; Engin Sahna
Journal:  Cardiovasc J Afr       Date:  2014 Sep-Oct       Impact factor: 1.167

8.  Caveolin and caveolae in age associated cardiovascular disease.

Authors:  Heidi N Fridolfsson; Hemal H Patel
Journal:  J Geriatr Cardiol       Date:  2013-03       Impact factor: 3.327

9.  Traumatic brain injury enhances neuroinflammation and lesion volume in caveolin deficient mice.

Authors:  Ingrid R Niesman; Jan M Schilling; Lee A Shapiro; Sarah E Kellerhals; Jacqueline A Bonds; Alexander M Kleschevnikov; Weihua Cui; April Voong; Stan Krajewski; Sameh S Ali; David M Roth; Hemal H Patel; Piyush M Patel; Brian P Head
Journal:  J Neuroinflammation       Date:  2014-03-03       Impact factor: 8.322

10.  Mutation in integrin-linked kinase (ILK(R211A)) and heat-shock protein 70 comprise a broadly cardioprotective complex.

Authors:  Alexandra Traister; Mark Walsh; Shabana Aafaqi; Mingliang Lu; Xiaojing Dai; Mark R Henkleman; Abdul Momen; Yu-Quing Zhou; Mansoor Husain; Sara Arab; Sara Piran; Gregory Hannigan; John G Coles
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.